In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|January 15, 2020
Horizon Discovery, Mammoth Biosciences Sign Collaboration and License Agreement
Author(s)BioPharm International Editors
Horizon Discovery Group and Mammoth Biosciences have signed a collaboration and license agreement aimed at the development of the next generation of engineered Chinese hamster ovary (CHO) cell lines to improve biotherapeutics production.
Advertisement
Horizon Discovery Group and Mammoth Biosciences have signed a collaboration and license agreement aimed at the development of the next generation of engineered Chinese hamster ovary (CHO) cell lines to improve biotherapeutics production.
In a Jan. 13, 2020 press release, the companies announced that the agreement will give Horizon access to Mammoth’s novel CRISPR platform to facilitate delivery of a new generation of genetically engineered CHO cells to be used for the production of biotherapeutics. As per the terms of the agreement, the companies will work together to optimize certain CRISPR tools for rapid development of proprietary CHO cell lines.
“Horizon is committed to leading the field in delivering the next generation of CHO cell lines to an industry where greater flexibility, increased speed to market and cost reduction are key drivers,” said Terry Pizzie, CEO of Horizon Discovery, in the press release. “We believe that our expertise in cell line engineering can be leveraged to address many of these issues and with the addition of Mammoth’s technology, the opportunity now exists for Horizon to become a disruptive provider of best in class engineered CHO cells to enable the production of next-generation biotherapeutics.”
Trevor Martin, CEO of Mammoth Biosciences, added, “At Mammoth, we are committed to democratizing access to novel CRISPR technologies. Our founding team has already pioneered the invention of a variety of new CRISPR systems and we’re thrilled to see systems used for applications like biotherapeutic production at Horizon. We look forward to working with the Horizon team to support innovation through its platform.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5